Abstract
Background. A reduced cardiac output in chronic heart failure (CHF) evokes renal NaCl and water retention, and, therefore, activates mechanisms promoting natriuresis. Atrial natriuretic peptide (ANP) is one such factor. We hypothesized that another NaCl sensitive endogenous natriuretic factor, i.e., marinobufagenin (MBG), a specific ligand of the α-1 subunit of Na/K ATPase (the main kidney isoform) and also a vasoconstrictor and cardiotonic substance, would be elevated in CHF patients in a graded manner with the severity of CHF. Methods and results. We measured the plasma levels of MBG, α-hANP, ouabain-like compound (OLC) and left ventricular (LV) volumes and ejection fraction in 23 consecutive hypertensive male patients with CHF. Plasma MBG levels exhibited progressive increases (0.59 ± 0.15, 1.08 ± 0.20, 1.35 ± 0.17 and 1.88 ± 0.05 nmol/l NYHA 1-4, respectively) and paralleled the changes of α-hANP. Conversely, plasma OLC did not exhibit such increases. Plasma MBG correlated with α-hANP (r = 0.82; P < 0.0001). Both MBG and α-hANP correlated with LV systolic (r = 0.55 and r = 0.47; P < 0.01) diameter and inversely with ejection fraction (r = -0.73 and r = -0.60; P < 0.01). OLC did not exhibit correlations with α-hANP or LV volumes, but positively correlated with systolic brachial blood pressure and with pulse pressure. Conclusions. In CHF, MBG exhibits progressive increases similar to ANP, varies with CHF severity and correlates with LV systolic function. We hypothesize, that, in CHF, the concurrent production of these two natriuretic hormones, a vasorelaxant, ANP, and a vasoconstrictor, MBG, potentiate each other's natriuretic effects, but may offset their vasoactive actions.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1189-1194 |
| Number of pages | 6 |
| Journal | Journal of Hypertension |
| Volume | 20 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2002 |
| Externally published | Yes |
Fingerprint
Keywords
- Bufanolides
- Heart failure
- Na(+)-K(+)-exchanging ATPase
- Natriuretic peptides
- Ouabain
- Steroids
ASJC Scopus subject areas
- Endocrinology
- Internal Medicine
Cite this
Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. / Fridman, Alexander I.; Matveev, Sergei A.; Agalakova, Natalia I.; Fedorova, Olga V.; Lakatta, Edward; Bagrov, Alexei Y.
In: Journal of Hypertension, Vol. 20, No. 6, 06.2002, p. 1189-1194.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity
AU - Fridman, Alexander I.
AU - Matveev, Sergei A.
AU - Agalakova, Natalia I.
AU - Fedorova, Olga V.
AU - Lakatta, Edward
AU - Bagrov, Alexei Y.
PY - 2002/6
Y1 - 2002/6
N2 - Background. A reduced cardiac output in chronic heart failure (CHF) evokes renal NaCl and water retention, and, therefore, activates mechanisms promoting natriuresis. Atrial natriuretic peptide (ANP) is one such factor. We hypothesized that another NaCl sensitive endogenous natriuretic factor, i.e., marinobufagenin (MBG), a specific ligand of the α-1 subunit of Na/K ATPase (the main kidney isoform) and also a vasoconstrictor and cardiotonic substance, would be elevated in CHF patients in a graded manner with the severity of CHF. Methods and results. We measured the plasma levels of MBG, α-hANP, ouabain-like compound (OLC) and left ventricular (LV) volumes and ejection fraction in 23 consecutive hypertensive male patients with CHF. Plasma MBG levels exhibited progressive increases (0.59 ± 0.15, 1.08 ± 0.20, 1.35 ± 0.17 and 1.88 ± 0.05 nmol/l NYHA 1-4, respectively) and paralleled the changes of α-hANP. Conversely, plasma OLC did not exhibit such increases. Plasma MBG correlated with α-hANP (r = 0.82; P < 0.0001). Both MBG and α-hANP correlated with LV systolic (r = 0.55 and r = 0.47; P < 0.01) diameter and inversely with ejection fraction (r = -0.73 and r = -0.60; P < 0.01). OLC did not exhibit correlations with α-hANP or LV volumes, but positively correlated with systolic brachial blood pressure and with pulse pressure. Conclusions. In CHF, MBG exhibits progressive increases similar to ANP, varies with CHF severity and correlates with LV systolic function. We hypothesize, that, in CHF, the concurrent production of these two natriuretic hormones, a vasorelaxant, ANP, and a vasoconstrictor, MBG, potentiate each other's natriuretic effects, but may offset their vasoactive actions.
AB - Background. A reduced cardiac output in chronic heart failure (CHF) evokes renal NaCl and water retention, and, therefore, activates mechanisms promoting natriuresis. Atrial natriuretic peptide (ANP) is one such factor. We hypothesized that another NaCl sensitive endogenous natriuretic factor, i.e., marinobufagenin (MBG), a specific ligand of the α-1 subunit of Na/K ATPase (the main kidney isoform) and also a vasoconstrictor and cardiotonic substance, would be elevated in CHF patients in a graded manner with the severity of CHF. Methods and results. We measured the plasma levels of MBG, α-hANP, ouabain-like compound (OLC) and left ventricular (LV) volumes and ejection fraction in 23 consecutive hypertensive male patients with CHF. Plasma MBG levels exhibited progressive increases (0.59 ± 0.15, 1.08 ± 0.20, 1.35 ± 0.17 and 1.88 ± 0.05 nmol/l NYHA 1-4, respectively) and paralleled the changes of α-hANP. Conversely, plasma OLC did not exhibit such increases. Plasma MBG correlated with α-hANP (r = 0.82; P < 0.0001). Both MBG and α-hANP correlated with LV systolic (r = 0.55 and r = 0.47; P < 0.01) diameter and inversely with ejection fraction (r = -0.73 and r = -0.60; P < 0.01). OLC did not exhibit correlations with α-hANP or LV volumes, but positively correlated with systolic brachial blood pressure and with pulse pressure. Conclusions. In CHF, MBG exhibits progressive increases similar to ANP, varies with CHF severity and correlates with LV systolic function. We hypothesize, that, in CHF, the concurrent production of these two natriuretic hormones, a vasorelaxant, ANP, and a vasoconstrictor, MBG, potentiate each other's natriuretic effects, but may offset their vasoactive actions.
KW - Bufanolides
KW - Heart failure
KW - Na(+)-K(+)-exchanging ATPase
KW - Natriuretic peptides
KW - Ouabain
KW - Steroids
UR - http://www.scopus.com/inward/record.url?scp=0036591601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036591601&partnerID=8YFLogxK
U2 - 10.1097/00004872-200206000-00032
DO - 10.1097/00004872-200206000-00032
M3 - Article
C2 - 12023690
AN - SCOPUS:0036591601
VL - 20
SP - 1189
EP - 1194
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - 6
ER -